Review Article

Role of Transient Receptor Potential Canonical Channel 6 (TRPC6) in Diabetic Kidney Disease by Regulating Podocyte Actin Cytoskeleton Rearrangement

Qian Wang1,2, Xuefei Tian3, Yuyang Wang4, Yan Wang5, Jialin Li1,2, Tingting Zhao1,2, and Ping Li1

1Beijing Key Laboratory for Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Sciences, China-Japan Friendship Hospital, Beijing 100029, China
2Beijing University of Chinese Medicine, Beijing 100029, China
3Section of Nephrology, Department of Internal Medicine, Yale University School of Medicine, New Haven, CT 06510, USA
4Department of Nephrology, Guang'anmen Hospital of China Academy of Traditional Chinese Medical Sciences, Beijing 100053, China
5Beijing Key Laboratory of Diabetes Research and Care, Center for Endocrine Metabolism and Immune Diseases, Luhe Hospital, Capital Medical University, Beijing 101149, China

Correspondence should be addressed to Tingting Zhao; ttfrfr@163.com and Ping Li; lp8675@163.com

Received 10 September 2019; Revised 17 December 2019; Accepted 23 December 2019; Published 4 January 2020

Academic Editor: Eric Hajduch

Copyright © 2020 Qian Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Podocyte injury is an important pathogenesis step causing proteinuric kidney diseases such as diabetic kidney disease (DKD). Actin cytoskeleton rearrangement in podocyte induced by multiple pathogenic factors is believed to be the key process resulting in glomerular injury. Many studies have recently shown that transient receptor potential canonical channel 6 (TRPC6) in podocyte plays a critical role in the development and progression of proteinuric kidney disease by regulating its actin cytoskeleton rearrangement. This review is aimed at summarizing the role of TRPC6 on DKD by regulating the podocyte actin cytoskeleton rearrangement, thereby help further broaden our views and understanding on the mechanism of DKD and provide a theoretic basis for exploring new therapeutic targets for DKD patients.

1. Introduction

Transient receptor potential canonical channel 6 (TRPC6) is a nonselective Ca2+ channel protein. In 2005, the gene mutation of TRPC6 in podocyte was firstly reported in the patients with focal segmental glomerulosclerosis (FSGS), suggesting the potential importance of TRPC6-mediated Ca2+ dynamics for podocyte function [1]. The abnormal expression of TRPC6 in podocyte is closely related to the occurrence of proteinuria in a variety of kidney diseases. It is known that TRPC6 can participate in podocyte injury by regulating the rearrangement of actin cytoskeleton and eventually leads to proteinuria. Podocytes are one of the important components for keeping glomerular filtration barrier integrity and maintenance of its size selectivity. The changes of podocyte number and/or structure of foot process have been demonstrated to be the main cause leading to glomerular proteinuria [2]. The highly organized actin backbone is the molecular basis for the normal structure of podocytes, and it is critical for the maintenance of their morphology and function. In recent years, numerous studies on podocyte have shown that actin cytoskeleton rearrangement induced by multiple pathogenic factors is the key alteration leading to podocyte injury [3, 4], and its mechanisms have remained elusive. Diabetic
kidney disease (DKD), one of the most common and severe complication of diabetes mellitus characterized by proteinuria, is the most important cause of end-stage renal disease (ESRD) throughout the world [5]. Podocyte injury is a typical manifestation and a core event in the progression of DKD [6]. More and more studies have shown that aberrant changes of TRPC6 in podocyte play an important role in the proteinuria formation and DKD progression. The mechanism may involve the rearrangement of podocyte actin cytoskeleton. However, the precise mechanism has not yet been determined, and further research is urgently needed.

2. The Role of TRPCs in Kidney Disease

The transient receptor potential (TRP) superfamily, that are involved in ion homeostasis and/or signal transduction, consists of six subfamilies: transient receptor potential cation channels (TRPCs), melastatin-related TRP proteins (TRPM), vanilloid-receptor-related TRP proteins (TRPV), the ankyrin transmembrane protein (TRPA), mucolipin (TRPML), and polycystin (TRPP) [7–9]. TRPCs are expressed in various segments of the human nephron; they are Ca2+-permeant cation channels that depolarize cells and increase intracellular calcium levels. There is a common consensus in TRPC proteins that these channels are potentiated by tyrosine kinase receptor-mediated activation of phospholipase C (PLC) or G protein-coupled receptors (GPCRs). Subsequently, phosphatidylinositol 4,5-bisphosphate (PIP2) is cleaved, liberating diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3) [7, 10]. There are seven different members of TRPCs identified in mammalian cells (TRPC1 through TRPC7) that are subdivided into four subgroups on the basis of protein sequence and function: TRPC1, TRPC2, TRPC4/5, and TRPC3, 6, 7. Each subunit of TRPCs structurally consists of six transmembrane regions, and a pore-forming region is present between the fifth and sixth transmembrane regions. The COOH and NH2-terminals of each TRPC protein subunits localize in the cytosolic portions of the cell [11]. The role of TRPCs in the pathogenesis of various renal disorders is summarized as below (Table 1).

The relationship between TRPC6 and nephropathy has been extensively investigated. TRPC6 mRNA was originally isolated from the brain of mice, and it was also identified in pulmonary artery smooth muscle cells (PASMCs) [22]. TRPC6 is confirmed to be a nonselective cation channel. A large body of studies [23, 24] strongly support that TRPC6 is an essential functional component of TRPCs in vascular smooth muscle cells. It has been shown that activated TRPC6 regulates its contractile function by permeating cation influx and depolarization of vascular smooth muscle cells [25]. Under the regulation of vasoactive hormones and autocrine/paracrine factors [4, 26], podocytes rearrange the F-actin, myosin, and α-actinin in the foot processes that change the size selectivity of the glomerular filtration barrier. The size-selectivity property of the glomerular filtration barrier by podocytes is fine-regulated by Ca2+ signals [27]. Therefore, TRPC6-mediated calcium influx can be directly associated with actin cytoskeleton rearrangement in podocytes that plays an important role in the proteinuria formation by affecting the intact of glomerular filtration barrier. The finding of FSGS caused by podocyte TRPC6 mutation has shown the proline at amino acid 112 in the TRPC6 protein is substituted with glutamine; it further confirms the importance of TRPC6 and potentially opens up a new view to explore the mechanism of podocyte injury in proteinuric kidney diseases [1].

TRPC6 is mainly expressed in the podocyte slit diaphragm (SD) and adjacent cell membrane. It responds to the activation of various GPCR cascades, resulting in Ca2+ influx into podocytes, which played an important role in regulating Ca2+ homeostasis in podocyte [21]. The canonical activation pathway for TRPC6 channels was established in 1999 by which certain DAG produced duringGPCRs mediated transduction cascades; it evoked an increase in the open probability (OP) of cell surface TRPC6 channels [28]. Membrane-permeable DAG analogs such as 1-oleoyl-snglycerol (OAG) increase TRPC6-mediated cationic currents in podocytes, which can be prevented by the inhibition of protein kinase C (PKC) [29]. It is likely that modulation by GPCRs entails two distinct processes, mobilization of TRPC6 channels to the cell surface, and an accompanied increase in the OP of TRPC6 channels already at the cell surface [30]. The gain-of-function (GOF) mutation of TRPC6 in podocyte leads to FSGS and massive proteinuria [1]. It is caused by the impairment of the Ca2+-dependent inactivation, resulting from the disruptions of TRPC6’s coiled-coil assembly. The excessive Ca2+ may contribute to structural damage in the podocytes [31]. Systematic analysis of TRPC6-related mutations showed that loss-of-function (LOF) of TRPC6 has the potential to induce disease [32], which may cause FSGS earlier than in GOF-type TRPC6 patients by interacting with actin cytoskeleton rearrangement during podocyte development [33]. Proteinuria in DKD is also closely related to the abnormal expression of TRPC6 in podocyte [34], and its mechanism is the main research hotspot at present [35].

3. TRPC6 Is Associated with DKD Podocyte Injury

TRPC6 channels in normal podocytes remain relatively stable until various stimuli trigger their activation [36]. Although the mechanism for TRPC6 activation is still quite unclear, abnormal changes of angiotensin II (Ang II), reactive oxygen species (ROS), and insulin in DKD setting can stimulate the overexpression of TRPC6 in podocytes. It causes a large amount of Ca2+ influx into podocyte, results in foot process effacement, podocyte loss, and other damages, that eventually leads to proteinuria development [36].

The levels of Ang II are highly increased in DKD glomerulus [37]. Interestingly, highly activated podocytes TRPC6 levels can be found in the Ang II-induced renal injury models [38]. Accordingly, using a type I DKD animal model induced by an injection of streptozotocin in Dahl salt-sensitive rats (STZ-SS), Ilatovskaya et al. [39] confirmed that Ang II could cause podocyte injury by Ca2+ influx through TRPC6, which were consistent with several other studies [34, 40, 41]. ROS plays an important role in the pathogenesis of DKD [42]. ROS, especially hydrogen peroxide forming from NADPH
TRPC6 overexpression has been observed in DKD setting podocytes, followed by podocyte injury. In conclusion, TRPC6 overexpression is located and plays a critical role leading to podocyte injury.

4. The Association between TRPC6 and Podocyte Actin Cytoskeleton Rearrangement in DKD

4.1. Actin Cytoskeleton Rearrangement Participates in DKD Podocyte Injury

4.1.1. Actin Cytoskeleton System and Its Rearrangement. The actin cytoskeleton system is the basic structural and functional unit that regulates cell morphology, cell adhesion, and motility. Different cytoskeletons are distributed in the cell bodies, primary processes, and secondary foot processes of podocytes [5]. As the main functional part of podocytes, foot processes are microfilaments composed of actin molecule especially the F-form actin (F-actin) [50]. A variety of podocyte cytoskeleton-associated proteins interact with F-actin to maintain normal podocyte actin cytoskeletal structure. Three groups of the podocyte cytoskeletal proteins are identified based on their upstream and downstream influencing pathways: the first group is the actin-binding proteins (ABP) that bind directly to actin by controlling its polymerization and depolymerization; these proteins include α-actinin, palladin, synaptopodin, three small guanosine triphosphatase (GTPase) of the Rho family (Rho A, Rac1, and Cdc42), and podocyte-associated talins. The second group is the upstream proteins of the

| TRPCs | Location of expression in kidney | Role in kidney | Kidney diseases or injuries associated with TRPC disorders | Objects of research | References |
|-------|---------------------------------|----------------|----------------------------------------------------------|---------------------|------------|
| TRPC1 | MC; PTEC; TAL.                   | Regulation of mesangial cell contractility; regulation of Ca^{2+} influx | Diabetic nephropathy | Human; ZDF rats; STZ-induced rats; Ang II-induced human MC | [12, 13]    |
| TRPC2 | P; CDEC; RF                     | A pseudogene and does not form functional channels in human | Autosomal dominant polycystic kidney disease; renal interstitial fibrosis | TRPC3−/− mice; UUO rats; GiPTEC cells with siTRPC3; IMCD3 cells treated with pcDNA/TRPC3; RF treated by the pyrazole-derivative TRPC3 blocker pyr3 | [14]        |
| TRPC3 | P; CDEC; RF                     | Regulation of Ca^{2+} influx | Progressive kidney diseases | Mouse MC line (CRL-1927) under high-glucose conditions | [15, 16]    |
| TRPC4 | MC                              | Regulation of Ca^{2+} entry; regulation of actin cytoskeleton rearrangement (need to be further investigated) | Unknown | Mouse podocytes treated by PS, LPS, and Cch | [17]        |
| TRPC5 | P                               | Focal segmental glomerulosclerosis | Progressive kidney diseases | TRPC5-KO mice by LPS injection; mouse podocytes treated by PS, LPS, and Cch | [18, 19]    |
| TRPC6 | P; EC; CDEC                    | Regulation of Ca^{2+} influx; regulation of actin cytoskeleton rearrangement | Focal segmental glomerulosclerosis; minimal change disease; membranous glomerulonephritis; type-1 diabetes; renal fibrosis | Human; PHN rats; C5b-9-attacked podocytes; HEK293 cells recombined with mouse GFP-TRPC6 | [20, 21]    |
| TRPC7 | Unknown                        | Unknown | Unknown | Unknown | References |

Abbreviations: MC: mesangial cell; PTEC: proximal tubule epithelial cells; TAL: thick ascending limb of the loop of Henle; P: podocytes; CDEC: collecting duct epithelial cells; RF: renal fibroblasts; EC: endothelial cells; ZDF: Zucker diabetic fatty; Ang II: angiotensin II; CiPTEC: human conditionally immortalized proximal tubular epithelial cells; IMCD3: mouse inner medullary collecting duct cell line; UUO: unilateral ureteral obstruction; LPS: lipopolysaccharide; PS: protamine sulfate; Cch: carbachol; PHN: the passive Heymann nephritis (PHN) model; HEK: human embryonic kidney.

Sources by various stimuli, could activate the podocyte TRPC6 in DKD [43]. NADPH oxidases such as Nox2 [44], Nox4 [45], and Nox5 [46] have been shown to be involved in the activation of TRPC6. The abnormalities of insulin signal transduction and pathway have been shown to play the pivotal role on DKD development and progression, as evident by the finding that specific deletion of the gene encoding the insulin receptor causes a loss of podocyte foot processes [46]. Studies have shown that insulin increases the TRPC6 expression on the surface of MPC-5 mouse podocyte cell lines, which is mediated by the NADPH oxidase-dependent ROS production [47]. Podocyte membrane protein urokinase and plasminogen activator receptor (uPAR) and its circulating form (suPAR) play an important role in the development of DKD as well. There were significantly increased uPAR and suPAR levels that were observed in glomeruli and sera of DKD patients, respectively [48], and suPAR could activate TRPC6 via the Nox2-dependent pathway [44]. Additionally, the direct damage of albumin to podocytes can increase the expression of TRPC6 as well [49]. Using an in vitro cell model of albumin overload, Chen et al. [49] confirmed that plasma albumin from proteinuric kidney disease can dramatically upregulate the expression of TRPC6 and Ca^{2+} influx in podocytes, followed by podocyte injury. In conclusion, TRPC6 overexpression has been observed in DKD setting that plays a critical role leading to podocyte injury.
actin-binding proteins; these proteins change the microfilament by regulating actin-binding protein not directly regulating actin; these proteins include SD proteins (nephrin, podocin, and CD2-related proteins) and focal adhesion-associated proteins (integrins, integrin-linked kinase, and focal adhesion kinase). The third group is a larger number of upstream proteins, including TRPCs, multiple kinases, proteases, and circulating permeability factors. They affect the microfilaments and microtubule structures of podocytes by regulating actin through certain signaling pathways. These proteins altogether regulate the polymerization, maintenance, and depolymerization of the actin cytoskeleton by different signaling pathways. The actin cytoskeleton proteins have two major functions depending their localization in the cell: one is the longitudinal actin microfilaments that provide structural support for cells with certain contractile and diastolic functions and also serve as a bridge linking intracellular molecular signaling pathways; the other one is a meshwork of actin filaments existing under the cell membrane that mediate transmembrane proteins and transmembrane signaling pathways [51]. The podocyte injury induced by many pathological factors causes the rearrangement of actin cytoskeleton, which disorganized the original structure of actin fibers, characterized as less-branched and shortened stalks. It resulted in increased mobility, decreased adhesion, increased cell width, foot process effacement, and even a large number of podocytes detachment. Consequently, the function of the glomerular filtration barrier is damaged which facilitates the development of proteinuria. Therefore, regulation or stabilization of the podocyte actin cytoskeleton structure is essential for maintaining normal glomerular filtration function.

4.1.2. Actin Cytoskeleton Rearrangement Results in Podocytes Injury in DKD. More and more evidences have shown that a decrease in podocyte number or density is the strongest predictor of DKD progression; it is positively correlated to the severity of proteinuria [52, 53]. Since podocytes are terminally differentiated epithelial cells and cannot undergo normal cell division [54], the occurrence of a large number of podocyte loss usually indicates that this kind of damage is irreversible. The mechanism by which the changes of podocyte numbers have not been clearly clarified, although apoptosis and active podocyte shedding are indicated the major causes. The apoptosis of podocytes is rarely observed using current experimental techniques available in vivo; the damage to podocyte mainly focuses on foot process effacement, podocyte hypertrophy, and podocyte loss; in addition, podocytes collected from the urine of a DKD rat model were cultured in a normal medium for 24 hours; their adherent growth and secreted specific proteins such as podocin were observed [55]. It indicates some podocytes in the urine still have cell activity under the disease state, and the cause of such podocyte reduction and podocyte urine may be the detachment of living podocytes from the glomerular basement membrane (GBM). However, the proportion of podocyte apoptosis and detachment in the mechanism of podocyte loss is still unknown; it can be suggested that the loss of active podocytes from the GBM is indeed an important mechanism for podocyte loss in DKD. As such, the key step of DKD podocyte loss may be attributed to the decreased ability of podocyte adhesion caused by various stimulating factors. It was also confirmed by two-photon microscopy in living zebrafish that the podocyte structure is relatively stable under normal conditions [56]. Dynamic podocyte movement could be observed while it was injured induced by unilateral ureteral ligation and adriamycin administration [57]; signals impairing the focal adhesion proteins can cause podocyte migration. The adhesion ability of podocyte is determined by the cell-matrix adhesion core structure complexes, including integrins/talins/actin, that allow the podocytes to attach to the GBM tightly to maintain the intact of glomerular filtration barrier. Any deficit in the structure components can impair the podocyte adhesion ability [50]. A variety of adhesion proteins existing in focal adhesion complexes, including α3β1 integrin, integrin-linked kinase, and talins, have all been shown to play a key role in podocyte development and function [58]. Integrin is the most widely studied adhesion protein till now. β1 containing integrins are highly expressed in podocytes and are essential for maintaining the structural integrity of the glomerulus [59]. It connects the GBM with the actin skeleton in podocyte cytoplasm through the focal adhesion complexes consisting of talins, vinculin, paxillin, and so on. α3β1 integrin has been found to be the major integrin form expressing on the surface of the podocyte foot process [60]. The extracellular domain of α3β1 binds to laminin and fibronectin on GBM, and the intracellular cytoplasmic domain of integrin subunit β1 binds to the focal adhesion complexes. Through this specific structure, α3β1 integrin can regulate the podocyte actin cytoskeleton rearrangement by “outside-in” and “inside-out” signaling pathways that alter the morphology and biological function of podocyte. The abnormal expression or activity of these adhesion proteins affect the function of integrins by changing the adhesion and diffusion of podocytes, regulating the rearrangement of actin cytoskeleton; it finally results in podocyte detachment from GBM. Studies have shown that the expression of α3β1 integrin is markedly reduced in both DKD patients and high glucose-induced podocyte injury rat models [61]. Additionally, the expression of α3β1 integrin mRNA and protein in the kidney tissue of DKD rats induced by STZ was significantly decreased [62]. The decreased β1 integrin may be accompanied by increased podocyte movement and reduced adhesion [63], and the rupture and stratification of GBM, that eventually caused the loss of podocytes. Recent studies have demonstrated that talin1, a 270 kDa focal adhesion molecule, is important for maintaining podocyte’s cytoskeletal stability, podocyte adhesion, and normal renal function [58]. Talin1 is required for integrin subunit β1 activation by binding its cytoplasmic domain; any change on talin1 will lead to integrin dysfunction. Talin1 has been recently shown to be associated with the TRPC6-mediated Ca2+-dependent calcineurin signal transduction pathway [64] that shed light on the further understanding of TRPC6 on the podocyte biological function.

Foot process effacement is the most important ultrastructural change following podocyte injury. Excluding some hereditary kidney disease, foot process effacement is thought
to help damaged podocytes that remain attached to GBM by enhancing the contraction of actin bundles, reducing the risk of podocyte shedding and limiting blood protein leakage into urine; it is an adaptive and reversible reaction [65]. However, the protective effect of this mechanism is limited. As podocytes fall off gradually, the bare GBM area increases accordingly; in the meantime, the abnormal connection of adjacent podocytes caused by the foot process effacement destroys the function of the original SD structure. All of these alternations eventually lead to proteinuria development. Actin cytoskeleton plays a key role in the changes of the foot process because of its high dynamic structure. Disorganized cytoskeletal rearrangement in podocyte causes extension, fusion, and contraction of the foot process [66, 67], followed by SD changes and proteinuria formation. F-actin in podocyte is often observed by an immunofluorescent technique stained with phalloidin. It has been demonstrated that there exist significantly aberrant F-actin pattern changes in DKD. The F-actin pattern alters from more than 90% of cell area filled with thick fibers or at least 2 thick fibers running under the nucleus, into no thick fibers or no fibers visible in the central area of the cell [58, 68–70]. However, the association between the specific modification of this stress fibers and the foot process effacement in vivo still requires to be further investigated. In the past decade, the Rho GTPase family proteins have been recognized as an important regulator of proteinuria development [71]; it was also observed in the DKD [72]. Among them, Rho A activation can lead to the fusion of foot processes and the reduction of actin-related proteins. Although there are many reports of the clinical applications for Rho kinase inhibitors on DKD improvement, the exact mechanism is still requires to be further investigated. In the past 6 years, it has been shown that the mechanism by which Cdc42 alters cell migration may be through regulation of the transcription factor serum response factor (SRF) to regulate β1 integrin expression at a transcriptional level [83]. While β1 integrin is one of the important molecules for the linkage between cell with extracellular matrix. This is a functional change in the Rho GTPase signaling pathway that alters cell migration by the Ca²⁺/CaMKII and its downstream molecules [84].

4.2. TRPC6-Mediated Calcium Influx Leads to DKD Podocyte Actin Cytoskeleton Rearrangement. As the importance of mechanism for actin cytoskeleton rearrangement in podocyte injury and proteinuria formation has been increasingly raised, Ca²⁺ signal transduction and homeostasis disorders in cells have been paid more and more attention that are considered as early events of podocyte injury [73]. Increased intracellular Ca²⁺ concentration in podocytes can be detected in many pathophysiological conditions, such as complement C5b-9 complex-mediated podocyte injury [74] and Ang II-induced podocyte injury [75]. Podocyte injury induced by protamine sulfate (PS) infusion into rat kidney, characterized by foot process effacement and SD fracture, is a classic transist podocyte injury animal model studying the foot process dynamics [76]. Studies on the mechanism of PS-induced podocyte injury have revealed an increased Ca²⁺ concentrations in both cultured podocyte [77] and isolated rat glomeruli [78]. Accordingly, a Ca²⁺/CaMKII pathway connects those injury factors to podocyte cytoskeleton rearrangement. TRPC6 has been identified to play a major role in the Ca²⁺ homeostasis of podocytes. Therefore, it is speculated that the intracellular Ca²⁺ level of podocytes regulated by TRPC6 plays a key role in maintaining the stability of actin cytoskeleton structure and podocyte biological function.

In order to clarify the consequences of TRPC6 dysregulation, it is important to understand the pathways for the downstream of its activation, both in normal conditions and in abnormal conditions. These are not fully understood and will clearly depend on the cell type examined. At present, the more recognized regulatory mechanism mainly includes two aspects. Firstly, TRPC6 interacts with actin cytoskeleton by the Ca²⁺-dependent Rho GTPase signaling; secondly, TRPC6 acts on podocyte adhesion proteins through the Ca²⁺-dependent calcineurin signal transduction pathway.

4.2.1. TRPC6 Interacts with Actin Cytoskeleton by the Ca²⁺-Dependent Rho GTPase Signaling. The role of Rho GTPase family proteins in the regulation of podocyte actin cytoskeleton has become a research hotspot in recent years [6]. The Rho GTPase family proteins, including Rho A, Rac1, and Cdc42, are major regulators of cytoskeletal dynamics [79]. Rho A can promote the formation of cell body and terminal actin-myosin stress fibers to regulate the stability of podocyte cytoskeleton; Rac1 and Cdc42 can regulate the formation of filopodium and lamellipodium, respectively, further promoting an increase of podocyte movement [80]. In a DKD mouse model, it has been observed an unbalanced activation of Rho A, Rac1, and Cdc42; these changes result in a rearrangement of the podocyte actin cytoskeleton and following foot process effacement. Either upregulation or inhibition of Rho A expression in podocytes can cause foot process effacement [81]; increased activity of Rac1 and Cdc42 may result in a significant decrease in F-actin expression [69, 82]. Studies have shown that the mechanism by which Cdc42 alters cell migration may be through regulation of the transcription factor serum response factor (SRF) to regulate β1 integrin expression at a transcriptional level [83]. While β1 integrin is one of the important molecules for the linkage between cell with extracellular matrix. This is a functional change in the Rho GTPase signaling pathway that alters cell migration by the Ca²⁺/CaMKII and its downstream molecules [84].
These two channels antagonized each other to regulate podocyte cytoskeletons. It was suggested that the imbalance of Rho A and Rac1 mediated by TRPC6 and TRPC5 could be one of the main causes leading to podocyte injury. However, the TRPC5 function described above has been challenged by some recent studies. Overexpression of TRPC5 in mice does not show proteinuria nor does it aggravate proteinuria induced by lipopolysaccharide (LPS) [19]. On the contrary, the loss of podocyte stress fibers was observed in the study of podocyte TRPC6 overexpression [21]. Recent study has established conditionally immortalized TRPC6 knockout (KO) podocytes isolated from TRPC6 KO mice [87]. Compared with wild-type (WT) TRPC6 podocytes, they have less cell motility, greater adhesion, and more actin stress fibers. This difference may be attributed to the difference in TRPC6 knockout level caused by siRNA technology used in previous studies, where some preservation of expression is seen. Heparan sulfate proteoglycan syndecan-4 (Sdc4) can interact with TRPC6, promotes its expression, and transports it to the cell surface in podocytes [88], resulting in reduced activation of Rho A and increased activation of Rac1, accompanied by increased generation of ROS and total β3-integrin [89]. All these results suggest that TRPC6 plays a more direct and critical role in podocyte actin cytoskeleton rearrangement.

Insulin can cause foot process effacement through controlling contraction of podocyte actin [46], which is mediated by TRPC6-dependent Ca2+ influx [90]. Recent studies have shown that TRPC6-dependent activation of the adenosine 5'-monophosphate-activated protein kinase (AMPK) signaling pathway is a novel mechanism, by which insulin mediates actin cytoskeletal rearrangement of podocyte. Phosphorylation of AMPKα2 induced by TRPC6 is required for activation of the insulin-dependent Rac1 signaling pathway in podocytes [91]. This study further elucidates that Rac1 may regulate F-actin rearrangement in podocytes by phosphorylation of actin regulatory proteins cofilin and P21 protein-activated kinase 1 (PAK1). Additionally, insulin can disrupt the interaction between microfilaments by activating protein kinase G type Ia (PKGIIa) subunits of rat podocytes, causing the podocyte actin cytoskeleton to rearrange [92]. Subsequent studies have confirmed that TRPC6 mediates the above pathway and considers insulin-dependent rearrangement of the cytoskeleton to be TRPC6 and PKGIIa-dependent [90].

4.2.2. TRPC6 Acts on Podocyte Adhesion Proteins by the Ca2+-Dependent Calcineurin Signal Transduction Pathway

Talins are one of the crucial adhesion proteins present in focal adhesion complexes. Talins bind and activate integrins, coupling it to the actin cytoskeleton [93]. There are two isoforms of talin in vertebrates: talin1 and talin2. Talin1 is widely expressed in all cytoplasm and can be cleaved by calpain, a calcium-dependent nonlysosomal cysteine protease [94]. It can control the affinity of actin binding through methyltransferase Ezh2 [95], playing an important role in mediating cell adhesion [96] and early embryonic development [97]. Talin2 is present at a higher level in the cerebral cortex, heart muscle, and kidneys. Both talin1 and talin2 are expressed in podocyte. Podocyte-specific deletion of talin1 presented the progressive proteinuria, foot process effacement, and kidney failure. Ablation of podocyte talin2 in mice lacking talin1 did not significantly change its phenotype, suggesting that talin1 function most likely predominates in normal podocyte physiology [58]. As one of the most important activated molecule on integrins, the change of talin1 can lead to integrins dysfunction, which is associated with the emergence of a variety of pathological phenomena including thrombosis, stroke, and cancer metastasis [98]. The recent study explores the importance of talin1 in the field of kidney disease for the first time [58] and demonstrated that mice lacking talin1 specifically in podocytes display severe proteinuria, foot process effacement, and renal failure. Although the lack of talin1 only caused a mild decrease in β1 integrin activation and podocyte adhesion, significant actin cytoskeleton rearrangement was observed in the isolated primary podocytes.

Calpain is a family of nonlysosomal cysteine proteases that are mainly activated by Ca2+; its overactivity is closely related to renal injury [99]. Calpain can induce calcineurin activation. Activated calcineurin is involved in proteinuria development by cleaving the podocyte actin cytoskeletal proteins. Calcium/calcineurin signaling pathway is speculated to play a crucial role in regulating the stability of podocyte cytoskeletal structure. The calcineurin inhibitor cyclosporin A (CsA) is one of the current mainstream treatments on proteinuric kidney diseases through its immunosuppressant role; meanwhile, the CsA’s protective role mediating by stabilizing podocyte actin cytoskeleton has been paid more and more attention as well. The signaling pathway of calcium/calcinurin is initiated by the movement of Ca2+ from the extracellular space into cells that mediates through TRPC6. After entry into the cells, Ca2+ binds to calcineurin and activates its phosphatase activity. Activated calcineurin dephosphorylates cytoplasmic nuclear factor of activated T-cell (NFATC) family members including NFATC1 through NFATC4, resulting in their translocation to the nucleus, where they function as transcription factors to regulate target gene expression. The downstream signaling pathway cascade of TRPC6 involves a Ca2+-dependent calcineurin signal transduction, which usually activates NFATCs. The important transcriptional target of NFATCs is TRPC6 itself that results in a harmful feedforward loop. However, this activation pathway has not been examined in podocytes. Accordingly, Verheijden et al. [64] examined whether the calcium-dependent protease calpain1 mediates TRPC6-dependent podocyte injury in human and experimental FSGS, as well as in cultured podocytes. They found that TRPC6-dependent Ca2+ influx increases the activity of calpain1 and leads to podocyte injury through loss of talin1 and activation of calcineurin. Their study highlights that TRPC6-dependent activation of calpain1 could be a key mechanism on the initiation and progression of podocyte injury in glomerular diseases. Overall, the authors suggest that both TRPC6 and calpain1 could be the future therapeutic targets in the treatment of proteinuria and prevention of glomerular injury in which they are overactivated. In addition, TRPC6 can activate calpain directly through
the extracellular signal-regulated kinase (ERK1/2) pathway in a Ca\(^{2+}\)-independent manner [100], thereby regulating cytoskeleton rearrangement, adhesion, and motility ability of podocyte [87] (Figure 1).

How do the TRPC6/calpain change in the DKD podocyte injury? Our results showed that there was a significantly loss of the podocyte talin1 on the mRNA level and protein level in a DKD mouse model (unpublished), which was strongly positively correlated to the severity of proteinuria and podocyte actin cytoskeleton rearrangement. Undoubtedly, further investigation on the podocyte actin cytoskeletal changes is very important in elucidating podocyte biological function, which will broaden our view and deepen our understanding on its role in the proteinuric kidney disease. In addition to the above-mentioned proteins, there are still many other cytoskeleton proteins that can participate in DKD podocyte injury through TRPC6-mediated calcium influx. For example, a recent study has found reduced MYH9 in DKD patients, type 2 DKD mouse model, and Ang II-stimulated podocytes [100]. MYH9 is one of the heavy chain isoforms of nonmuscle myosin II (NM II) involved in cell migration, adhesion, and cellular actin cytoskeleton contraction [101]. It indicates that the decrease of MYH9 expression mediated by Ang II in DKD can induce F-actin rearrangement in podocytes and subsequent proteinuria, which may be related to TRPC6-dependent Ca\(^{2+}\) influx due to NOX4-mediated ROS production.

5. Conclusions

In conclusion, TRPC6 plays a crucial role in podocyte injury in proteinuric kidney diseases and it participates in proteinuria formation by regulating its actin cytoskeleton rearrangement. Although the investigation on the role and mechanism of TRPC6 in DKD podocyte actin cytoskeleton rearrangement is still in its infancy, these results all suggest that it is of great value to study the mechanism of DKD podocyte injury targeting TRPC6 that provide a potential therapeutic target on TRPC6 for DKD. It is noteworthy that type 1 DKD model Akita mice lacking TRPC6 have only a short-term renal protective effect by inhibiting albuminuria and reducing tubular injury, while mesangial dilatation and insulin resistance subsequently aggravate renal injury, suggesting that LOF-type mutation of TRPC6 has the same pathogenic effect in type 1 DKD [102]. Most studies available focus on the experiments from type 1 DKD animal models in vivo and podocyte culture in vitro; the researches on human DKD and type 2 DKD animal models are limited. Therefore,
how to accurately clarify the role of TRPC6 in the development of DKD, especially in type 2 DKD, and elucidate the specific regulatory mechanism of TRPC6 on actin cytoskeleton rearrangement of DKD podocytes are the key points for further investigation.

Conflicts of Interest
The authors confirm that there is no conflict of interests.

Acknowledgments
This work was supported by the National Natural Science Foundation of China grants 81620108031 (Dr. Ping Li) and 81973627 (Dr. Tingting Zhao).

References
[1] M. Winn, P. Conlon, K. Lynn et al., “A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis,” Science, vol. 308, no. 5729, pp. 1801–1804, 2005.
[2] W. H. Fissell and J. H. Miner, “What is the glomerular ultrafiltration barrier?,” Journal of the American Society of Nephrology, vol. 29, no. 9, pp. 2262–2264, 2018.
[3] Y. Maezawa and K. Yokote, “Human glomerular transcriptome of diabetic kidneys: can the podocyte cytoskeleton be a therapeutic target?,” Journal of Diabetes Investigation, vol. 10, no. 2, pp. 224–226, 2019.
[4] C. Faul, K. Asanuma, E. Yanagida-Asanuma, K. Kim, and P. Mundel, “Actin up: regulation of podocyte structure and function by components of the actin cytoskeleton,” Trends in Cell Biology, vol. 17, no. 9, pp. 428–437, 2007.
[5] R. Z. Alicic, M. T. Rooney, and K. R. Tuttle, “Diabetic kidney disease: challenges, progress, and possibilities,” Clinical Journal of the American Society of Nephrology, vol. 12, no. 12, pp. 2032–2045, 2017.
[6] A. Greka and P. Mundel, “Cell biology and pathology of podocytes,” Annual Review of Physiology, vol. 74, no. 1, pp. 299–323, 2012.
[7] D. E. Clapham, “TRP channels as cellular sensors,” Nature, vol. 426, no. 6966, pp. 517–524, 2003.
[8] B. Nilius, G. Owsianik, T. Voets, and J. A. Peters, “Transient receptor potential cation channels in disease,” Physiological Reviews, vol. 87, no. 1, pp. 165–217, 2007.
[9] T. E. Woudenberg-Vrenken, R. J. M. Bindels, and J. G. J. Hoenderop, “The role of transient receptor potential channels in kidney disease,” Nature Reviews Nephrology, vol. 5, no. 8, pp. 441–449, 2009.
[10] M. Schaefer, T. D. Plant, A. G. Obukhov, T. Hofmann, T. Guerdemann, and G. Schultz, “Receptor-mediated regulation of the nonselective cation channels TRPC4 and TRPC5,” Journal of Biological Chemistry, vol. 275, no. 23, pp. 17517–17526, 2000.
[11] J. Zheng, “Molecular mechanism of TRP channels,” Comprehensive Physiology, vol. 3, no. 1, pp. 221–242, 2013.
[12] J. Du, S. Sours-Brothers, R. Coleman et al., “Canonical transient receptor potential 1 channel is involved in contractile function of glomerular mesangial cells,” Journal of the American Society of Nephrology, vol. 18, no. 5, pp. 1437–1445, 2007.
[13] M. Niehof and J. Borlak, “HNF4α and the Ca-channel TRPC1 are novel disease candidate genes in diabetic nephropathy,” Diabetes, vol. 57, no. 4, pp. 1069–1077, 2008.
[14] E. R. Liman and H. Innan, “Relaxed selective pressure on an essential component of pheromone transduction in primate evolution,” Proceedings of the National Academy of Sciences, vol. 100, no. 6, pp. 3328–3332, 2003.
[15] Z. Li, J. Zhou, Y. Li, F. Yang, X. Lian, and W. Liu, “Mitochondrial TRPC3 promotes cell proliferation by regulating the mitochondrial calcium and metabolism in renal polycystin-2 knockdown cells,” International Urology and Nephrology, vol. 51, no. 6, pp. 1059–1070, 2019.
[16] Y. Saliba, R. Karam, V. Smyrta et al., “Evidence of a role for fibroblast transient receptor potential canonical 3 Ca2+ channel in renal fibrosis,” Journal of the American Society of Nephrology, vol. 26, no. 8, pp. 1855–1876, 2015.
[17] H. Soni and A. Adeniyi, “Urotensin II-induced store-operated Ca2+ entry contributes to glomerular mesangial cell proliferation and extracellular matrix protein production under high glucose conditions,” Scientific Reports, vol. 7, no. 1, article 18049, 2017.
[18] T. Schaldecker, S. Kim, C. Tarabanis et al., “Inhibition of the TRPC5 ion channel protects the kidney filter,” The Journal of Clinical Investigation, vol. 123, no. 12, pp. 5298–5309, 2013.
[19] X. Wang, R. R. Dande, H. Yu et al., “TRPC5 does not cause or aggravate glomerular disease,” Journal of the American Society of Nephrology, vol. 29, no. 2, pp. 409–415, 2018.
[20] J. Reiser, K. R. Polu, C. C. Möller et al., “TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function,” Nature Genetics, vol. 37, no. 7, pp. 739–744, 2005.
[21] C. C. Möller, C. Wei, M. M. Altintas et al., “Induction of TRPC6 channel in acquired forms of proteinuric kidney disease,” Journal of the American Society of Nephrology, vol. 18, no. 1, pp. 29–36, 2007.
[22] L. C. Ng and A. M. Gurney, “Store-operated channels mediate Ca2+ influx and contraction in rat pulmonary artery,” Circulation Research, vol. 89, no. 10, pp. 923–929, 2001.
[23] R. Sonneveld, J. G. Hoenderop, A. M. Isidori et al., “Sildenafil prevents podocyte Injury via PPAR-γ-Mediated TRPC6 inhibition,” Journal of the American Society of Nephrology, vol. 28, no. 5, pp. 1491–1505, 2017.
[24] H. Roshanravan, E. Y. Kim, and S. E. Dryer, “20-Hydroxyeicosatetraenoic acid (20-HETA) modulates canonical transient receptor potential-6 (TRPC6) channels in podocytes,” Frontiers in Physiology, vol. 7, p. 351, 2016.
[25] A. Piwowska, D. Rogacka, I. Audzeyenka, M. Kasztan, S. Angielski, and M. Jankowski, “Insulin increases glomerular filtration barrier permeability through PKGα-dependent mobilization of BKCa channels in cultured rat podocytes,” Biochimica et Biophysica Acta, vol. 1852, no. 8, pp. 1599–1609, 2015.
[26] B. Lewko and J. Stepinski, “Cyclic GMP signaling in podocytes,” Microscopy Research and Technique, vol. 57, no. 4, pp. 232–235, 2002.
[27] J. L. Hunt, M. R. Pollak, and B. M. Denker, “ Cultured podocytes establish a size-selective barrier regulated by specific signaling pathways and demonstrate synchronized barrier assembly in a calcium switch model of junction formation,” Journal of the American Society of Nephrology, vol. 16, no. 6, pp. 1593–1602, 2005.
[28] T. Hofmann, A. G. Obukhov, M. Schaefer, C. Harteneck, T. Gudermann, and G. Schultz, “Direct activation of human TRPC6 and TRPC3 channels by diacylglycerol,” *Nature*, vol. 397, no. 6716, pp. 259–263, 1999.

[29] S. M. Bousquet, M. Monet, and G. Boulay, “Protein kinase C-dependent phosphorylation of transient receptor potential canonical 6 (TRPC6) on serine 448 causes channel inhibition,” *The Journal of Biological Chemistry*, vol. 285, no. 52, pp. 40534–40543, 2010.

[30] S. E. Dryer, H. Roshanravan, and E. Y. Kim, “TRPC channels: Regulation, dysregulation and contributions to chronic kidney disease,” *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1865, no. 6, pp. 1041–1066, 2019.

[31] O. K. Polat, M. Uno, T. Maruyama et al., “A novel mammalian homolog of Drosophila transient repor...,” *The American Society of Nephrology*, vol. 30, no. 9, pp. 1587–1603, 2019.

[32] M. Riehle, A. K. Büscher, B.-O. Gohlke et al., “TRPC6 G757D loss-of-function mutation associates with FSGS,” *Journal of the American Society of Nephrology*, vol. 27, no. 9, pp. 2771–2783, 2016.

[33] Z. Liu, J. Yang, X. Zhang, P. Xu, T. Zhang, and Z. Yang, “Developmental changes in the expression and function of TRPC6 channels related the F-actin organization during differentiation in podocytes,” *Cell Calcium*, vol. 58, no. 6, pp. 541–548, 2015.

[34] R. Sonneveld, J. van der Vlag, M. P. A. Baltissen et al., “Glucose Specifically Regulates TRPC6 Expression in the Podocyte in an AngII-Dependent Manner,” *The American Journal of Pathology*, vol. 184, no. 6, pp. 1715–1726, 2014.

[35] G. Boulay, X. Zhu, M. Peyton et al., “Cloning and expression of a novel mammalian homolog of Drosophila transient receptor potential (Trp) involved in calcium entry secondary to activation of receptors coupled by the Gq class of G protein,” *The Journal of Biological Chemistry*, vol. 272, no. 47, pp. 29672–29680, 1997.

[36] D. V. Ilatovskaya and A. Staruschenko, “TRPC6 channel as an emerging determinant of the podocyte injury susceptibility in kidney diseases,” *American Journal of Physiology. Renal Physiology*, vol. 309, no. 5, pp. F393–F397, 2015.

[37] G. Qiu and Z. Ji, “AngII-induced glomerular mesangial cell proliferation inhibited by losartan via changes in intracellular calcium ion concentration,” *Clinical and Experimental Medicine*, vol. 14, no. 2, pp. 169–176, 2014.

[38] J. Eckel, P. J. Lavin, E. A. Finch et al., “TRPC6 enhances angiotensin II-induced albuminuria,” *Journal of the American Society of Nephrology*, vol. 22, no. 3, pp. 526–535, 2011.

[39] D. V. Ilatovskaya, V. Levchenko, A. Lowing, L. S. Shyuksiy, O. Palygin, and A. Staruschenko, “Podocyte injury in diabetic nephropathy: implications of angiotensin II - dependent activation of TRPC channels,” *Scientific Reports*, vol. 5, no. 1, 2015.

[40] D. V. Ilatovskaya, O. Palygin, V. Chubinskiy-Nadezhdin et al., “Angiotensin II has acute effects on TRPC6 channels in podocytes of freshly isolated glomeruli,” *Kidney International*, vol. 86, no. 3, pp. 506–514, 2014.

[41] D. V. Ilatovskaya, O. Palygin, V. Levchenko, B. T. Endres, and A. Staruschenko, “The role of angiotensin II in glomerular volume dynamics and podocyte calcium handling,” *Scientific Reports*, vol. 7, no. 1, p. 299, 2017.

[42] N. A. Calcutt, M. E. Cooper, T. S. Kern, and A. M. Schmidt, “Therapies for hyperglycaemia-induced diabetic complications: from animal models to clinical trials,” *Nature Reviews. Drug Discovery*, vol. 8, no. 5, pp. 417–429, 2009.

[43] D. V. Ilatovskaya, G. Blass, O. Palygin et al., “A NOX4/TRPC6 pathway in podocyte calcium regulation and renal damage in diabetic kidney disease,” *Journal of the American Society of Nephrology*, vol. 29, no. 7, pp. 1917–1927, 2018.

[44] E. Y. Kim, N. Hassanazadeh Khayyat, and S. E. Dryer, “Mechanisms underlying modulation of podocyte TRPC6 channels by suPAR: role of NADPH oxidases and Src family tyrosine kinases,” *Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease*, vol. 1864, no. 10, pp. 3527–3536, 2018.

[45] J. C. Jha, C. Banal, J. Okabe et al., “NADPH oxidase Nox5 accelerates renal injury in diabetic nephropathy,” *Diabetes*, vol. 66, no. 10, pp. 2691–2703, 2017.

[46] G. I. Welsh, L. J. Hale, V. Eremina et al., “Insulin signaling to the glomerular podocyte is critical for normal kidney function,” *Cell Metabolism*, vol. 12, no. 4, pp. 329–340, 2010.

[47] E. Y. Kim, M. Anderson, and S. E. Dryer, “Insulin increases surface expression of TRPC6 channels in podocytes: role of NADPH oxidases and reactive oxygen species,” *American Journal of Physiology. Renal Physiology*, vol. 302, no. 3, pp. F298–F307, 2012.

[48] R. R. Dande, V. Peev, M. M. Altintas, and J. Reiser, “Soluble urokinase receptor and the kidney response in diabetes mellitus,” *Journal Diabetes Research*, vol. 2017, article 3232848, 2017.

[49] S. Chen, F. He, H. Wang et al., “Calcium entry via TRPC6 mediates albumin overload-induced endoplasmic reticulum stress and apoptosis in podocytes,” *Cell Calcium*, vol. 50, no. 6, pp. 523–529, 2011.

[50] C. Schell and T. B. Huber, “The evolving complexity of the podocyte cytoskeleton,” *Journal of the American Society of Nephrology*, vol. 28, no. 11, pp. 3166–3174, 2017.

[51] P. Garg, “A review of podocyte biology,” *American Journal of Nephrology*, vol. 47, no. 1, pp. 3–13, 2018.

[52] C. Lavoz, Y. S. Matus, M. Orejudo et al., “Interleukin-17A blockade reduces albuminuria and kidney injury in an accelerated model of diabetic nephropathy,” *Kidney International*, vol. 95, no. 6, pp. 1418–1432, 2019.

[53] J. Fu, C. Wei, K. Lee et al., “Comparison of glomerular and podocyte mRNA profiles in streptozotocin-induced diabet...,” *Journal of the American Society of Nephrology*, vol. 27, no. 4, pp. 1006–1014, 2019.

[54] W. Kriz, “Podocyte is the major culprit accounting for the progression of chronic renal disease,” *Microscopy Research and Technique*, vol. 57, no. 4, pp. 189–195, 2002.

[55] D. Yu, A. Petermann, U. Hunter, S. Rong, S. J. Shankland, and J. Floege, “Urinary podocyte loss is a more specific marker of ongoing glomerular damage than proteinuria,” *Journal of the American Society of Nephrology*, vol. 16, no. 6, pp. 1733–1741, 2005.

[56] N. Endlich, O. Simon, A. Göpferich et al., “Two-photon microscopy reveals stationary podocytes in living zebrafish larvae,” *Journal of the American Society of Nephrology*, vol. 25, no. 4, pp. 681–686, 2014.

[57] M. J. Hackl, J. L. Burford, K. Villanueva et al., “Tracking the fate of glomerular epithelial cells in vivo using serial multi-photon imaging in new mouse models with fluorescent
lineage tags,” *Nature Medicine*, vol. 19, no. 12, pp. 1661–1666, 2013.

[58] X. Tian, J. J. Kim, S. M. Monkley et al., “Podocyte-associated talin1 is critical for glomerular filtration barrier maintenance,” *The Journal of Clinical Investigation*, vol. 124, no. 3, pp. 1098–1113, 2014.

[59] A. Pozzi, G. Jarad, G. W. Moeckel et al., “β1 integrin expression by podocytes is required to maintain glomerular structural integrity,” *Developmental Biology*, vol. 316, no. 2, pp. 288–301, 2008.

[60] M. Regoli and M. Bendayan, “Alterations in the expression of the α5β1 integrin in certain membrane domains of the glomerular epithelial cells (podocytes) in diabetes mellitus,” *Diabetologia*, vol. 40, no. 1, pp. 15–22, 1997.

[61] P. V. Kitsiou, A. K. Tzinia, W. G. Stetler-Stevenson et al., “Glucose-induced changes in integrins and matrix-related functions in cultured human glomerular epithelial cells,” *American Journal of Physiology*, vol. 284, no. 4, pp. F671–F679, 2003.

[62] J. Chen, Y. Chen, Y. Luo, D. Gui, J. Huang, and D. He, “Astragaloside IV ameliorates diabetic nephropathy involving protection of podocytes in streptozotocin induced diabetic rats,” *European Journal of Pharmacology*, vol. 736, pp. 86–94, 2014.

[63] Z. Li, L. Zhang, W. Shi et al., “Spironolactone inhibits podocyte motility via decreasing integrin β1 and increasing integrin β3 in podocytes under high-glucose conditions,” *Molecular Medicine Reports*, vol. 12, no. 5, pp. 6849–6854, 2015.

[64] K. A. T. Verheijden, R. Sonneveld, M. Bakker-van Bebber, N. Huang, X. Zhang, Y. Jiang et al., “A. Pozzi, G. Jarad, G. W. Moeckel et al., “β1 integrin expression by podocytes is required to maintain glomerular structural integrity,” *Developmental Biology*, vol. 316, no. 2, pp. 288–301, 2008.

[65] W. Kriz, I. Shirato, M. Nagata, M. LeHir, and K. V. Lemley, “The podocyte's response to stress: the enigma of foot process effacement,” *American Journal of Physiology*, vol. 304, no. 4, pp. F333–F347, 2013.

[66] C. V. Falkenberg, E. U. Azeloglu, M. Stothers et al., “Fragility of foot process morphology in kidney podocytes arises from chaotic spatial propagation of cytoskeletal instability,” *Plos Computational Biology*, vol. 13, no. 3, article e1005433, 2017.

[67] M. Hu, M. Fan, J. Zhen et al., “FAK contributes to proteinuria in hypercholesterolaemic rats and modulates podocyte F-actin re-organization via activating p38 in response to ox-LDL,” *Journal of Cellular and Molecular Medicine*, vol. 21, no. 3, pp. 552–567, 2017.

[68] M. Verderame, D. Alcorta, M. Egnor, K. Smith, and R. Pollack, “Cytoskeletal F-actin patterns quantitated with fluorescein isothiocyanate-phalloidin in normal and transformed cells,” *Proceedings of the National Academy of Sciences of the United States of America*, vol. 77, no. 11, pp. 6624–6628, 1980.

[69] J. Lin, Y. Shi, H. Peng et al., “Loss of PTEN promotes podocyte cytoskeletal rearrangement, aggravating diabetic nephropathy,” *The Journal of Pathology*, vol. 236, no. 1, pp. 30–40, 2015.

[70] N. Huang, X. Zhang, Y. Jiang et al., “Increased levels of serum pigment epithelium-derived factor aggravate proteinuria via induction of podocyte actin rearrangement,” *International Urology and Nephrology*, vol. 51, no. 2, pp. 359–367, 2019.

[71] A. Babelova, F. Jansen, K. Sander et al., “Activation of Rac-1 and RhoA contributes to podocyte injury in chronic kidney disease,” *PLoS One*, vol. 8, no. 11, article e80328, 2013.

[72] R. Komers, “Rho kinase inhibition in diabetic kidney disease,” *British Journal of Clinical Pharmacology*, vol. 76, no. 4, pp. 551–559, 2013.

[73] D. Kerjaschki, “Polycation-induced dislocation of slit diaphragms and formation of cell junctions in rat kidney glomeruli: the effects of low temperature, divalent cations, calciocholine, and cytochalasin B,” *Laboratory Investigation; A Journal Of Technical Methods And Pathology*, vol. 39, no. 5, pp. 430–440, 1978.

[74] A. V. Cybulsky, J. V. Bonventre, R. J. Quig, W. Lieberthal, and D. J. Salant, “Cytosolic calcium and protein kinase C reduce complement-mediated glomerular epithelial injury,” *Kidney International*, vol. 38, no. 5, pp. 803–811, 1990.

[75] A. Henger, T. Huber, K. G. Fischer et al., “Angiotensin II increases the cytosolic calcium activity in rat podocytes in culture,” *Kidney International*, vol. 52, no. 3, pp. 687–693, 1997.

[76] R. Verma, I. Kovari, A. Soofi, D. Nihalani, K. Patrice, and L. B. Holzman, “Nephrin ectodomain engagement results in Src kinase activation, nephrin phosphorylation, Nck recruitment, and actin polymerization,” *The Journal of Clinical Investigation*, vol. 116, no. 5, pp. 1346–1359, 2006.

[77] F. Rüdiger, R. Greger, R. Nitschke, A. Henger, P. Mundel, and H. Pavenstädt, “Polycations induce calcium signaling in glomerular podocytes,” *Kidney International*, vol. 56, no. 5, pp. 1700–1709, 1999.

[78] J. Vassiliadis, C. Bracken, D. Matthews, S. O’Brien, S. Schiavi, and S. Wawersik, “Calcium mediates glomerular filtration through calcineurin and mTORC2/Akt signaling,” *Journal of the American Society of Nephrology*, vol. 22, no. 8, pp. 1453–1461, 2011.

[79] S. Etienne-Manneville and A. Hall, “Rho GTPases in cell biology,” *Nature*, vol. 420, pp. 629–635, 2002.

[80] G. I. Welsh and M. A. Saleem, “The podocyte cytoskeleton—key to a functioning glomerulus in health and disease,” *Nature Reviews. Nephrology*, vol. 8, no. 1, pp. 14–21, 2011.

[81] L. Wang, M. J. Ellis, J. A. Gomez et al., “Mechanisms of the proteinuria induced by Rho GTPases,” *Kidney International*, vol. 81, no. 11, pp. 1075–1085, 2012.

[82] S. M. Blattner, J. B. Hodgkin, M. Nishio et al., “Divergent functions of the Rho GTPases Rac1 and Cdc42 in podocyte injury,” *Kidney International*, vol. 84, no. 5, pp. 920–930, 2013.

[83] N. Reymond, J. H. Im, R. Garg et al., “Cdc42 promotes transendothelial migration of cancer cells through β1 integrin,” *The Journal of Cell Biology*, vol. 199, no. 4, pp. 653–668, 2012.

[84] Y. Pan, S. Jiang, Q. Hou et al., “Dissection of glomerular transcriptional profile in patients with diabetic nephropathy: SRGAP2a protects podocyte structure and function,” *Diabetes*, vol. 67, no. 4, pp. 717–730, 2018.

[85] L. Jiang, J. Ding, H. Tsai et al., “Over-expressing transient receptor potential cation channel 6 in podocytes induces cytoskeleton rearrangement through increases of intracellular Ca2+ and RhoA activation,” *Experimental Biology and Medicine*, vol. 236, no. 2, pp. 184–193, 2011.

[86] D. Tian, S. M. P. Jacobo, D. Billing et al., “Antagonistic regulation of actin dynamics and cell motility by TRPC5 and TRPC6 channels,” *Science Signaling*, vol. 3, no. 145, article ra77, 2010.
[87] L. K. Farmer, R. Rollason, D. J. Whitcomb et al., “TRPC6 binds to and activates calpain, independent of its channel activity, and regulates podocyte cytoskeleton, cell adhesion, and motility,” Journal of the American Society of Nephrology, vol. 30, no. 10, pp. 1910–1924, 2019.

[88] Y. Liu, F. Echtermeyer, F. Thilo et al., “The proteoglycan syndecan 4 regulates transient receptor potential canonical 6 channels via Rhoo/Rho-associated protein kinase signaling,” Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 32, no. 2, pp. 378–385, 2012.

[89] E. Y. Kim, H. Roshanravan, and S. E. Dryer, “Syndecan-4 ectodomain evokes mobilization of podocyte TRPC6 channels and their associated pathways: an essential role for integrin signaling,” Biochimica et Biophysica Acta, vol. 1853, no. 10, pp. 2610–2620, 2015.

[90] D. Rogacka, I. Audzeyenka, P. Rachubik et al., “Insulin increases filtration barrier permeability via TRPC6-dependent activation of PKGα signaling pathways,” Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease, vol. 1863, no. 6, pp. 1312–1325, 2017.

[91] P. Rachubik, M. Szrejder, D. Rogacka et al., “The TRPC6-AMPK pathway is involved in insulin-dependent cytoskeleton reorganization and glucose uptake in cultured rat podocytes,” Cellular Physiology and Biochemistry, vol. 51, no. 1, pp. 393–410, 2018.

[92] S. H. Francis, J. L. Busch, J. D. Corbin, and D. Sibley, “cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action,” Pharmacological Reviews, vol. 62, no. 3, pp. 525–563, 2010.

[93] R. E. Gough and B. T. Goult, “The tale of two talins - two isoforms to fine-tune integrin signalling,” FEBS Letters, vol. 592, no. 12, pp. 2108–2125, 2018.

[94] S. J. Franco, M. A. Rodgers, B. J. Perrin et al., “Calpain-mediated proteolysis of talin regulates adhesion dynamics,” Nature Cell Biology, vol. 6, no. 10, pp. 977–983, 2004.

[95] M. Gunawan, N. Venkatesan, J. T. Loh et al., “The methyltransferase Ezh2 controls cell adhesion and migration through direct methylation of the extranuclear regulatory protein talin,” Nature Immunology, vol. 16, no. 5, pp. 505–516, 2015.

[96] A. M. Manso, H. Okada, F. M. Sakamoto et al., “Loss of mouse cardiomyocyte talin-1 and talin-2 leads to β-1 integrin reduction, costameric instability, and dilated cardiomyopathy,” Proceedings of the National Academy of Sciences, vol. 114, no. 30, pp. E6250–E6259, 2017.

[97] S. J. Monkley, X. H. Zhou, S. J. Kinston et al., “Disruption of the talin gene arrests mouse development at the gastrulation stage,” Developmental Dynamics: an Official Publication of the American Association of Anatomists, vol. 219, no. 4, pp. 560–574, 2000.

[98] D. Cox, M. Brennan, and N. Moran, “Integrins as therapeutic targets: lessons and opportunities,” Nature Reviews. Drug Discovery, vol. 9, no. 10, pp. 804–820, 2010.

[99] J. Peltier, A. Bellocq, J. Perez et al., “Calpain activation and secretion promote glomerular injury in experimental glomerulonephritis: evidence from calpastatin-transgenic mice,” Journal of the American Society of Nephrology, vol. 17, no. 12, pp. 3415–3423, 2006.

[100] J. S. Kang, S. J. Lee, J. H. Lee et al., “Angiotensin II-mediated MYH9 downregulation causes structural and functional podocyte injury in diabetic kidney disease,” Scientific Reports, vol. 9, no. 1, article 7679, p. 7679, 2019.

[101] N. Singh, N. Nainani, P. Arora, and R. C. Venuto, “CKD in MYH9-Related Disorders,” American Journal of Kidney Diseases, vol. 54, no. 4, pp. 732–740, 2009.

[102] L. Wang, J. H. Chang, A. F. Buckley, and R. F. Spurney, “Knockout of TRPC6 promotes insulin resistance and exacerbates glomerular injury in Akita mice,” Kidney International, vol. 95, no. 2, pp. 321–332, 2019.